Coeptis Therapeutics, a pharmaceutical company focused on the development of innovative therapeutics and technologies, went public via a SPAC merger with Bull Horn in a $175m deal. "Today's announcement is a key milestone for Coeptis as it gains access to the capital needed to advance our product portfolio highlighted by CD38-GEAR-NK and CD38-Diagnostic. The combination of CD38-GEAR-NK and CD38-Diagnostic has the potential to provide a more targeted administration of anti-CD38 mAbs in the treatment of cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia," David Mehalick, Coeptis Therapeutics President and CEO.